Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Beam Therapeutics Inc. (BEAM : NSDQ)

• Company Description    Beam Therapeutics Inc. is a biotechnology company. It engages in developing precision genetic medicines through base editing. Beam Therapeutics Inc. is based in Cambridge, Massachusetts. Number of Employees: 511

• Price / Volume Information    Yesterday's Closing Price: $28.64 Daily Weekly Monthly 20 Day Moving Average: 2,236,264 shares Shares Outstanding: 102.88 (millions) Market Capitalization: $2,946.45 (millions) Beta: 2.26 52 Week High: $36.44 52 Week Low: $15.35 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -5.04% -9.68% 12 Week -0.97% -8.45% Year To Date 3.32% -8.23%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 238 Main Street - Cambridge,MA 02142 USA ph: 857-327-8775 fax: - investors@beamtx.com https://beamtx.com

• General Corporate Information    Officers John Evans - Chief Executive Officer and Director Sravan Emany - Chief Financial Officer Bethany Cavanagh - Senior Vice President; Finance Graham Cooper - Director Mark Fishman - Director Peer Information Beam Therapeutics Inc. (CORR.) Beam Therapeutics Inc. (RSPI) Beam Therapeutics Inc. (CGXP) Beam Therapeutics Inc. (BGEN) Beam Therapeutics Inc. (GTBP) Beam Therapeutics Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 07373V105 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/04/26 Share - Related Items Shares Outstanding: 102.88 Most Recent Split Date: (:1) Beta: 2.26 Market Capitalization: $2,946.45 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.03 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.23 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.53 Price/Cash Flow: - Price / Sales: 17.96 EPS Growth vs. Year Ago Period: 26.61% vs. Previous Quarter: -810.00% Sales Growth vs. Year Ago Period: 324.87% vs. Previous Quarter: -72.19% ROE 03/31/26 - -29.00 12/31/25 - -30.65 09/30/25 - -42.86 ROA 03/31/26 - -22.61 12/31/25 - -23.73 09/30/25 - -31.45 Current Ratio 03/31/26 - 16.99 12/31/25 - 13.09 09/30/25 - 6.02 Quick Ratio 03/31/26 - 16.99 12/31/25 - 13.09 09/30/25 - 6.02 Operating Margin 03/31/26 - -195.22 12/31/25 - -239.82 09/30/25 - -744.41 Net Margin 03/31/26 - -39.66 12/31/25 - -57.24 09/30/25 - -744.41 Pre-Tax Margin 03/31/26 - -40.23 12/31/25 - -57.24 09/30/25 - -742.72 Book Value 03/31/26 - 11.32 12/31/25 - 12.20 09/30/25 - 9.52 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.09 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 7.92 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©